# Study of CD30 CAR for Relapsed/Refractory CD30+ HL and CD30+ NHL

> **NCT02690545** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **UNC Lineberger Comprehensive Cancer Center** · enrollment: 38 (actual)

## Conditions studied

- Lymphoma
- Lymphoma, Non-Hodgkin
- Immune System Diseases
- Immunoproliferative Disorders
- Lymphatic Diseases
- Lymphoproliferative Disorders
- Neoplasms
- Neoplasms by Histologic Type

## Interventions

- **BIOLOGICAL:** ATLCAR.CD30 cells

## Key facts

- **NCT ID:** NCT02690545
- **Lead sponsor:** UNC Lineberger Comprehensive Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2016-08-26
- **Primary completion:** 2025-12-16
- **Final completion:** 2039-11-04
- **Target enrollment:** 38 (ACTUAL)
- **Last updated:** 2026-01-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02690545

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02690545, "Study of CD30 CAR for Relapsed/Refractory CD30+ HL and CD30+ NHL". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02690545. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*